<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369728">
  <stage>Registered</stage>
  <submitdate>5/12/2015</submitdate>
  <approvaldate>15/12/2015</approvaldate>
  <actrnumber>ACTRN12615001356550</actrnumber>
  <trial_identification>
    <studytitle>A prospective study comparing topical corticosteroids with a combination of topical corticosteroids plus the trial agent (TA) in morphea.</studytitle>
    <scientifictitle>Assessing the response of limited scleroderma to manipulation of
the kynurenine pathway. A prospective study comparing topical
corticosteroids vs topical corticosteroids/tranilast</scientifictitle>
    <utrn>U1111-1177-3064</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>MORPHEA</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Cross body trial of topical betamethasone valerate 0.1% vs topical betamethasone valerate 0.1% and tranilast 1% applied twice daily over a period of 3 months. Monitoring is to be done monthly via LoSCAT scores, laboratory tests and cream return. All other prescribed therapy is to be continued. The dosage of both agents is one finger tip unit (0.5g) per hand sized region (125 sqcm)</interventions>
    <comparator>Topical betamethasone valerate 0.1% (active control) applied twice daily over a period of 3 months.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) score</outcome>
      <timepoint>3 months after commencing therapy</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Therapeutic safety is to be monitored via clinical review and laboratory testing</outcome>
      <timepoint>Assessment is performed at monthly intervals after commecing therapy for a period of 3 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adults with morphea greater than 18 yrs of age
Non pregnant
Non lactating
No significant renal, hematological or hepatic disease</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Less than 18 yrs of age
Pregnant or lactating females
Known sensitivity to the trial agent
Significant renal, hematological or hepatic disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomization by computer</concealment>
    <sequence>Computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Other</assignment>
    <designfeatures>Randomized double blinded split body study with betamethasone valerate 0.1% applied at one site and betamethasone valerate o.1% , tranilast 1% applied to a contralateral site</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods>The staistical parameters used to determine the number of participants are:
Alpha value. 0.05
Power 90
Size effect 0.7
Statistical significance p&lt; 0.05</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2015</actualstartdate>
    <anticipatedenddate>31/12/2018</anticipatedenddate>
    <actualenddate>27/02/2017</actualenddate>
    <samplesize>11</samplesize>
    <actualsamplesize>11</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2017</anticipatedlastvisitdate>
    <actuallastvisitdate>22/06/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Greenslopes Private Hospital - Greenslopes</hospital>
    <postcode>4120 - Greenslopes</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>DR ROWLAND NOAKES</primarysponsorname>
    <primarysponsoraddress>QUEENSLAND INSTITUTE OF DERMATOLOGY
GREENSLOPES PRIVATE HOSPITAL
GREENSLOPES QLD 4120</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>DR ROWLAND NOAKES</fundingname>
      <fundingaddress>QUEENSLAND INSTITUTE OF DERMATOLOGY
GREENSLOPES PRIVATE HOSPITAL
GREENSLOPES QLD 4120</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a cross body trial to compare the safety and efficacy of topical tranilast in morphea. This agent is an established pharmaceutical with a good safety record which has been available in Japan and Korea for 20-30 yrs but has never been marketed in Australia. It has approval for the management of keloid and hypertrophic scars in these countries. There are publshed reports of efficacy in morphea. 

The trial involves the application of a corticosteroid cream to one involved site on the body with the application of a cream containing both corticosteroid and the trial agent at an alternate site for a period of 3 months. Monthly clinical and laboratory assessments will be performed over this time. All currently prescribed treatments will be continued during this period.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>GREENSLOPES RESEARCH AND ETHICS COMMITTEE</ethicname>
      <ethicaddress>GREENSLOPES PRIVATE HOSPITAL
NEWDEGATE STREET
GREENSLOPES. QLD 4120</ethicaddress>
      <ethicapprovaldate>14/10/2015</ethicapprovaldate>
      <hrec>PROTOCOL14/70</hrec>
      <ethicsubmitdate>8/12/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>ROWLAND NOAKES</name>
      <address>QUEENSLAND INSTITUTE OF DERMATOLOGY
GREENSLOPES PRIVATE HOSPITAL
GREENSLOPES QLD 4120</address>
      <phone>+61733294400</phone>
      <fax>+61733294455</fax>
      <email>ky_n_urenine@hotmail.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>ANGELA BOND</name>
      <address>QUEENSLAND INSTITUTE OF DERMATOLOGY
GREENSLOPES PRIVATE HOSPITAL
GREENSLOPES QLD 4120</address>
      <phone>+61733294400</phone>
      <fax>+61733294455</fax>
      <email>abond@qiderm.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>ROWLAND NOAKES</name>
      <address>QUEENSLAND INSTITUTE OF DERMATOLOGY
GREENSLOPES PRIVATE HOSPITAL
GREENSLOPES QLD 4120</address>
      <phone>+61733294400</phone>
      <fax>+61733294455</fax>
      <email>ky_n_urenine@hotmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>ROWLAND NOAKES</name>
      <address>QUEENSLAND INSTITUTE OF DERMATOLOGY
GREENSLOPES PRIVATE HOSPITAL
GREENSLOPES QLD 4120</address>
      <phone>+61419677741</phone>
      <fax>61733294455</fax>
      <email>ky_n_urenine@hotmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>